Edwards Lifesciences Corporation

BRSE:001065343 Stock Report

Market Cap: CHF 39.4b

Edwards Lifesciences Valuation

Is 001065343 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 001065343 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 001065343 (CHF65.79) is trading above our estimate of fair value (CHF60.62)

Significantly Below Fair Value: 001065343 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 001065343?

Key metric: As 001065343 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 001065343. This is calculated by dividing 001065343's market cap by their current earnings.
What is 001065343's PE Ratio?
PE Ratio28.2x
EarningsUS$1.57b
Market CapUS$44.12b

Price to Earnings Ratio vs Peers

How does 001065343's PE Ratio compare to its peers?

The above table shows the PE ratio for 001065343 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average42.8x
STMN Straumann Holding
63.1x21.2%CHF 18.2b
SOON Sonova Holding
31.2x11.4%CHF 17.6b
MOVE Medacta Group
40.5x21.1%CHF 2.1b
ALC Alcon
36.3x9.9%CHF 37.6b
001065343 Edwards Lifesciences
28.2x3.3%CHF 44.1b

Price-To-Earnings vs Peers: 001065343 is good value based on its Price-To-Earnings Ratio (28.2x) compared to the peer average (42.8x).

Price to Earnings Ratio vs Industry

How does 001065343's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
001065343 28.2xIndustry Avg. 29.6xNo. of Companies9PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 001065343 is good value based on its Price-To-Earnings Ratio (28.2x) compared to the European Medical Equipment industry average (29.6x).

Price to Earnings Ratio vs Fair Ratio

What is 001065343's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

001065343 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio28.2x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 001065343's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 001065343 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 65.79
CHF 71.41
+8.5%
9.5%CHF 87.18CHF 61.24n/a29
Dec ’25n/a
CHF 67.57
0%
9.8%CHF 85.38CHF 55.57n/a28
Nov ’25CHF 58.47
CHF 66.04
+12.9%
9.8%CHF 83.72CHF 54.49n/a28
Oct ’25n/a
CHF 65.72
0%
9.6%CHF 81.91CHF 55.00n/a27
Sep ’25n/a
CHF 71.49
0%
11.1%CHF 89.02CHF 57.05n/a27
Aug ’25n/a
CHF 71.49
0%
11.1%CHF 89.02CHF 57.05n/a27
Jul ’25n/a
CHF 85.47
0%
10.2%CHF 95.21CHF 62.29n/a27
Jun ’25n/a
CHF 87.23
0%
9.6%CHF 96.67CHF 65.95n/a28
May ’25n/a
CHF 86.84
0%
9.5%CHF 95.60CHF 66.46n/a28
Apr ’25n/a
CHF 83.52
0%
9.2%CHF 94.69CHF 64.93n/a28
Mar ’25n/a
CHF 80.72
0%
8.3%CHF 92.85CHF 63.67n/a28
Feb ’25n/a
CHF 68.65
0%
12.3%CHF 82.34CHF 48.89n/a28
Jan ’25n/a
CHF 68.17
0%
12.3%CHF 82.21CHF 48.81n/a28
Dec ’24n/a
CHF 70.45
0%
14.4%CHF 89.58CHF 50.06n/a28
Nov ’24n/a
CHF 73.94
0%
13.8%CHF 92.60CHF 57.19CHF 58.4727
Oct ’24n/a
CHF 87.56
0%
8.8%CHF 100.69CHF 68.65n/a26
Sep ’24n/a
CHF 84.10
0%
8.8%CHF 96.28CHF 65.64n/a24
Aug ’24n/a
CHF 84.10
0%
8.8%CHF 96.28CHF 65.64n/a24
Jul ’24n/a
CHF 84.88
0%
8.5%CHF 95.14CHF 66.15n/a23
Jun ’24n/a
CHF 84.88
0%
8.5%CHF 95.14CHF 66.15n/a23
May ’24CHF 76.76
CHF 82.88
+8.0%
8.7%CHF 93.85CHF 65.25n/a22
Apr ’24n/a
CHF 79.78
0%
9.6%CHF 91.89CHF 61.57n/a22
Mar ’24n/a
CHF 82.84
0%
13.5%CHF 119.96CHF 61.82n/a22
Feb ’24n/a
CHF 80.50
0%
14.1%CHF 118.14CHF 59.98n/a22
Jan ’24n/a
CHF 84.64
0%
16.0%CHF 120.51CHF 63.04n/a23
Dec ’23n/a
CHF 89.32
0%
13.8%CHF 121.81CHF 68.40n/a22

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 15:41
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Edwards Lifesciences Corporation is covered by 74 analysts. 33 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James Francis MainwaringAtlantic Equities LLP
David RescottBaird
Ishan MajumdarBaptista Research